Signifi cant pain, activity limitation, and disability in patients with acute and chronic gouty arthritis lower health-related quality of life. Although many effective therapies are available for gouty arthritis, medication errors are common. One goal of therapy is to reduce the frequency of gout fl ares by lowering serum uric acid. Further, evidence suggests that the quality of care provided to patients with gout may also impact health-related quality of life. This article reviews evidence concerning quality of care and quality of life for patients with gout.
Introduction
Gouty arthritis is characterized by acute, intermittent, infl ammatory arthritis that evolves over many years to chronic infl ammatory polyarthritis. In severe cases, tophaceous urate deposits and infl ammatory arthritis may lead to deformity, disability, and radiographic destruction. An estimated 5 million Americans have gout, with an estimated $27 million spent each year on new acute cases [1, 2] . In 2002, gout accounted for 1.4 million US outpatient visits [3] . These data indicate that gout is a signifi cant public health problem in the United States and perhaps worldwide. Although effi cacious treatment options are available to treat gout, failure to provide appropriate care is quite evident.
Practical ways to qualitatively examine the effectiveness of gout treatments include the use of evidence-based quality indicators (QIs); the examination of objective outcomes, such as the normalization of serum urate, delay, and reversal of radiographic joint damage; or the assessment of patient-reported outcomes, such as gout-specifi c, health-related quality of life (HRQoL), pain, and function. Very large samples are needed to determine improvement in outcomes, however, making this approach diffi cult for most health care systems in terms of costs and feasibility. Another limitation of this approach is that these outcome data are often infrequently collected as part of regular clinical care. Therefore, quality of care is assessed by examining errors in medication use or by assessing compliance with QIs.
Gouty arthritis morbidity mostly involves acute arthritis fl ares, chronic polyarthritis, tophaceous masses, and joint destruction. Thus, arthritis impacts the HRQoL of patients with gout. Patients with gouty arthritis also have signifi cant medical comorbidity load, which can also impact HRQoL. This article focuses on recent advances in quality of care and quality of life (QoL) for patients with gout.
Quality of Care for Gout
The Agency for Health Care Research and Quality defi nes quality of care as "The degree to which health care services for individuals and populations increase the likelihood of desired health outcomes and are consistent with current professional knowledge" [4] . The following section examines data regarding errors in medication prescription and laboratory monitoring, as well as noncompliance with evidence-based QIs for gout [4] .
Errors in medication prescription and laboratory monitoring
The pharmacologic treatment of gouty arthritis can be broadly divided into two categories: urate-lowering agents (eg, the xanthine oxidase inhibitor, allopurinol, followed by uricosurics, such as probenecid, sulfi npyrazone, and benzbromarone [not available in the Untied States]) and anti-infl ammatory medications (eg, nonsteroidal antiinfl ammatory drugs [NSAIDs], corticosteroids, and colchicine) used for acute fl ares and prophylaxis against fl ares during initiation of urate-lowering agents. Long-term therapy with urate-lowering agents (usually lifelong) is indicated in patients with gouty arthritis with ≥ 2 attacks/ year, radiographic destruction, or tophaceous gout [5, 6] . Treatment intends to reduce the frequency of acute fl ares by achieving a target serum uric acid level of ≤ 6 mg/dL, a cut-off supported by published evidence.
A recent systematic review examining the optimal target for serum uric acid level included 23 studies, four of which were randomized controlled trials [7] . Evidence from these studies showed an association between higher serum uric acid level and higher risk of gout. A lower level of serum uric acid was associated with decreased frequency of gout fl ares, decreased requirement of NSAIDs during fl ares, and resolution of tophi. Thus, achieving a target serum uric acid ≤ 6 mg/dL improves outcomes in gout and therefore is an important cornerstone of treatment.
Several studies have described errors in medication use and monitoring in emergency room (ER), inpatient, and outpatient settings. Chin et al. [8] prospectively studied inappropriate ER drug use in 981 patients in Chicago, fi nding that the most common discharge diagnosis for which potentially inappropriate drugs were added included musculoskeletal disorders, back pain, gout, and allergy/urticaria.
Smith et al. [9] performed an audit of 93 patients who were prescribed allopurinol at the time of hospital discharge in Australia. In this study of 49 men and 44 women, the average age was 77 years (minimum age, 65 years). In 47% of patients, the allopurinol dose was higher than recommended for the creatinine clearance, whereas in 40% of patients it was lower, indicating that allopurinol doses were not adjusted to creatinine clearances.
Mikuls et al.
[10] used the MEDMARX database (an internet-accessible error-reporting program designed for use by US hospitals and health care systems) to examine medication errors in the use of gout-related medications. They studied errors in the use of allopurinol, colchicine, probenecid, and sulfi npyrazone from 1999 to 2003. Of 582,397 medication errors, 891 (0.15%) errors were related to goutspecifi c medications. The most frequent medication errors occurred with allopurinol (n = 524) followed by colchicine (n = 315). The most common errors in colchicine and allopurinol use included illegible or incomplete orders, followed by excessive dosing, often in patients with renal failure. Compared with other treatment errors, physicians were more commonly implicated in medication errors related to gout (23%-39%) than other conditions (7%), whereas nurses were less often responsible for these errors (23%-27% for gout vs 50% for other conditions; P < 0.0001).
In contrast to other studies, Ly et al.
[11] found a moderately good compliance of gout care with the New Zealand Rheumatology Association (NZRA) guidelines. This retrospective chart review in 100 patients who met American College of Rheumatology preliminary criteria for gout included two cohorts, 50 patients who received colchicine for acute gouty arthritis (mean age, 58 y) and 50 patients with renal impairment who were on long-term prophylactic colchicine (mean age, 66 y; creatinine ≥ 2 mg/dL or creatinine clearance ≤ 50 mL/min). For treatment of acute gouty arthritis, colchicine was prescribed in 96% (48 of 50) of patients at a total dosage of ≤ 2.5 mg/d. Appropriate complete blood count and creatine kinase laboratory testing was performed after six months in 38 (76%) of 50 patients receiving long-term colchicine, in accordance with NZRA guidelines. Laboratory monitoring identifi ed one patient who developed colchicine-induced myopathy.
In a retrospective study, Dalbeth et al. [12] examined whether the allopurinol dosing in patients attending a rheumatology clinic was adjusted to creatinine clearance. Of 227 patients, 22 (10%) patients received a lower-thanrecommended dosage of allopurinol, 161 (71%) received the recommended dosage, and 44 (14%) received dosages higher than recommended. Serum uric acid levels were lower in those receiving higher-than-recommended dosages of allopurinol (38% reached the target uric acid level) compared with lower-dosage and recommended-dosage groups (19% and 15%, respectively, reached the target uric acid level). Differences were also signifi cant between the higher-and recommended-dosage groups (P < 0.01).
Singh et al.
[13] studied a cohort of 643 veterans with gout who received a new allopurinol prescription. Quality medication use and monitoring were assessed, using published evidence ranging from randomized controlled trials to pharmacokinetic data. Of 643 patients with gout, 297 (46%) patients were prescribed allopurinol continuously; the rest had one or more discontinuations lasting 30 days or longer during follow-up. Only 20% of patients with gout reached the target uric acid level of ≤ 6 mg/dL, 20% of patients had a uric acid check and did not reach the target uric acid level, and 61% of patients had no serum uric acid check. Colchicine or NSAID prophylaxis was started before or on the day of new allopurinol prescription only in 169 (48%) of 643 patients with gout.
Sarawate et al. [14••] analyzed data from a managed care plan in which the average age of patients with gout was 57 years, 76% were men, and the average Deyo-Charlson Index score was 0.9. In 3651 patients with newly diagnosed gout who received allopurinol, 87% of patients discontinued therapy (defi ned as more than 1.5 times duration between refi lls compared with the last refi ll duration). Patients had bimodal distribution for allopurinol use (ie, most had medication-possession ratios [MPRs] of < 10% or > 90%). In those with newly diagnosed gout taking allopurinol, 83% of patients had no claim for serum uric acid testing within 6 months of allopurinol initiation. Fiftythree percent of patients with gout and renal impairment (creatinine > 2 mg/dL or a diagnostic code for renal impairment) received allopurinol dosage ≥ 300 mg/d (higher than the recommended dose).
Roddy et al. [15] studied the adherence to European League Against Rheumatism guidelines for the management of chronic gout using two general practice populations in the United Kingdom. Of 4249 patients completing the questionnaire, 488 reported gout or acute attacks and 164 confi rmed to have gout on clinical examination by an expert. Overall, 44 (30%) of 164 patients were taking allopurinol. Of 10 patients with tophaceous gout, two (20%) patients were taking allopurinol and four (40%) patients had taken allopurinol in the past. Thirtyone (70%) current allopurinol users were taking a dosage of 300 mg/d, whereas two (25%) of eight patients took prophylactic colchicine and/or an NSAID during initial allopurinol prescription.
